This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Miner, K. M. Articles by Nicolson, G. L. Search for Related Content PubMed PubMed Citation Articles by Miner, K. M. Articles by Nicolson, G. L.

Differences in the Sensitivities of Murine Metastatic Lymphoma/Lymphosarcoma Variants to Macrophage-mediated Cytolysis and/or Cytostasis

Department of Tumor Biology, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030

A metastasizing animal tumor model for large cell lymphoma or lymphosarcoma has been established by sequential selection in vivo of the RAW117 parental cell line in BALB/c mice for enhanced colonization of liver or lung and in vitro for lack of binding to immobilized lectins. The parental RAW117 and selected sublines and clones derived from these were compared for their sensitivities in vitro to polyinosinic:polycytidylic acid-activated syngeneic macrophages in cytolysis and cytostasis assays. Activated but not unactivated macrophages had differing effects on RAW117 sublines and clones. The least metastatic (parental) cell line was the most sensitive to activated macrophage-mediated cytolysis and cytostasis, while the most metastatic subline was the least sensitive in these assays. Intermediate metastatic sublines or clones were usually less sensitive in one or both of the assays. These antitumor activities were negligible at 24 hr in the continuous presence of polyinosinic: polycytidylic acid but were clearly apparent by 48 to 72 hr. The results suggest that differential sensitivity to host macrophage surveillance mechanisms can occur in malignant cell subpopulations.

¹ NIH Postdoctoral Fellow (IF32-CA06697). Present address: Merck Institute, P. O. Box 2000, Bldg. 80W, Rahway, N. J. 07065.

² Recipient of National Cancer Institute Grant RO1-CA29571. To whom requests for reprints should be addressed.

Received 8/16/82. Accepted 2/ 1/83.